From: Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics
Study | Number of FLT3 mutants/total cases studied | Treatment | Demographics of those patients with FLT3-ITD | + FLT3-ITD assessment of risk |
---|---|---|---|---|
Fröhling, et al [21] | 119/523 all comers (22.8%) 71/224 NC AML (32%) | AML Study Group (AMLSG) AML HD93 AML HD98-A | - Associated with high WBC - Associated with de novo AML - Increased bone marrow and peripheral blood blasts - Increased LDH | Hazard ratio (HR) Remission duration 2.35 |
Kainz, et al [23] | 26/100 (26%) 16/53 NC AML (30%) | Various protocols | - Increased in M4 (50%) - Increased LDH - WBC >10 K | OR CR 0.31 Relapse rate 8.3 OS 0.17 |
Ciolli, et al [24] | 25/100 (25%) | Various protocols | - WBC > 30 K - Decreased incidence of secondary AML - Female predominance - Increased LDH | HR RFS 3.1 Post remission survival 2.1 |
Stirewelt, et al [26] | 48/151 (31.8%) | Southwest Oncology Group SWOG 9333 SWOG 9500 | - High bone marrow blasts - High peripheral blood blasts - WBC >30 K | HR OS 1.35 RFS 1.7 |
Whitman, et al [27] | 23/82 (28%) | CALGB protocol | - All patients evaluated had NC AML, age <60, and de novo AML - Median age 37 yo - N = 8 FLT3ITD/- | No clear evidence in difference between groups, but trend towards decreased OS with FLT3ITD/- |
Thiede, et al [28] | 200/979 (20.4%) | Various protocols | - Increased in M5 - WBC >50 K - Increased bone marrow blasts | OR Mut/wt ratio 1 - all ages OS 1.8 DFS 3.2 - age < 60 DFS 4.2 Mut/wt ratio 2 - all ages OS 2.8 DFS 8 - age < 60 DFS6.9 |